STOCK TITAN

BlackRock discloses 7.7% Ginkgo Bioworks stake (NYSE: DNA)

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A stock. BlackRock’s reporting business units collectively beneficially own 4,122,510 shares, representing 7.7% of the Class A shares outstanding. They hold sole voting power over 4,013,128 shares and sole dispositive power over 4,122,510 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client’s interest exceeds five percent of Ginkgo Bioworks’ outstanding common shares. The position is reported by BlackRock as a parent holding company through relevant subsidiaries identified in an exhibit, and the filing is signed by Managing Director Spencer Fleming.

Positive

  • None.

Negative

  • None.
Beneficial ownership 4,122,510 shares Class A stock beneficially owned by BlackRock reporting business units
Percent of class 7.7% Portion of Ginkgo Bioworks Class A shares beneficially owned
Sole voting power 4,013,128 shares Shares for which BlackRock has sole power to vote or direct the vote
Sole dispositive power 4,122,510 shares Shares for which BlackRock has sole power to dispose or direct disposition
Shared voting power 0 Shares with shared power to vote or direct the vote
Shared dispositive power 0 Shares with shared power to dispose or direct disposition
beneficially owned financial
"this reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting power financial
"Sole Voting Power 4,013,128.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"Sole Dispositive Power 4,122,510.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
parent holding company financial
"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"
Schedule 13G regulatory
"In accordance with SEC Release No. 34-39538 this schedule reflects the securities"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What percentage of Ginkgo Bioworks (DNA) does BlackRock report owning?

BlackRock reports beneficial ownership of 7.7% of Ginkgo Bioworks’ Class A stock. This corresponds to 4,122,510 shares as disclosed in the Schedule 13G/A, reflecting holdings of certain BlackRock business units.

How many Ginkgo Bioworks (DNA) shares does BlackRock have voting power over?

BlackRock has sole voting power over 4,013,128 Ginkgo Bioworks Class A shares. It reports no shared voting power, meaning all reported voting authority is held solely by BlackRock’s reporting business units.

What is the total number of Ginkgo Bioworks (DNA) shares BlackRock can dispose of?

BlackRock has sole dispositive power over 4,122,510 Ginkgo Bioworks Class A shares. The filing shows no shared dispositive power, indicating exclusive control over potential sales or transfers of these shares.

Do any single BlackRock clients own over 5% of Ginkgo Bioworks (DNA)?

No, the filing states that while various persons may receive dividends or sale proceeds, no one person’s interest in Ginkgo Bioworks common stock exceeds five percent of the total outstanding common shares.

Who signed the amended Ginkgo Bioworks (DNA) Schedule 13G for BlackRock?

The Schedule 13G/A was signed by Spencer Fleming, a Managing Director at BlackRock, Inc. The signature date disclosed in the filing is 07/30/2026, confirming BlackRock’s reporting responsibility.

What does the Ginkgo Bioworks (DNA) Schedule 13G/A say about BlackRock subsidiaries?

The filing notes BlackRock is a parent holding company and refers to Exhibit 99 for identification and classification of the subsidiaries through which the reported Ginkgo Bioworks shares are held.





37611X209

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



BlackRock, Inc.
Signature:Spencer Fleming
Name/Title:Managing Director
Date:07/30/2026
Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7